acute myocardial infraction
Conditions
Interventions
experimental group:The experimental group received additional use of Kuanxiong Qiwu Ji (produced by Subo Pharmaceutical Industries Ltd.), 2 puffs under the tongue, 3 times a day for a duration of 3 mo
control group:Control group patients received routine medication after PCI procedure and addition of placebo (produced by Subo Pharmaceutical Industries Ltd.), 2 puffs under the tongue, 3 times a day
Sponsors
Tai'an Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Age > 18 years; 2. Underwent emergency PCI treatment; 3. Patients have normal cognition; 4. No use of Kuanxiong Qiwu Ji before surgery; 5. Patients agree to the study plan and sign relevant informed consent form
Exclusion criteria
Exclusion criteria: (1) Allergy to Kuanxiong Qiwu Ji ; (2) Patients with cardiogenic shock; (3) Severe liver or kidney dysfunction; (4) Patients who have used Kuanxiong Qiwu Ji before surgery; (5) Patients with contraindications for the use of Kuanxiong Qiwu Ji ; (6) Patients with poor compliance or unable to complete the treatment as required.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left ventricular end diastolic dimension;Left ventricular end-diastolic volume;Left ventricular end-systolic volume;Left Ventricular Ejection Fractions;left ventricular reconstruction index; | — |
Secondary
| Measure | Time frame |
|---|---|
| peak O2;The partial pressure of CO2 in tidal volume during rest and exercise;Anaerobic Threshold;VO2/HR;VE/Vco2;Metabolic equivalents;Heart Rate;Cardiac Index;Cardiac Output;Stroke Volume;Mean Artery Pressure;PaO2/FiO2; | — |
Countries
China
Contacts
Public ContactZhong Xu
Tai'an Central Hospital
Outcome results
None listed